Group 1 - The core point of the article is that Huili Pharmaceutical (688553) has filed an international patent application for a dual anti-cytokine fusion protein and its uses, with the application number PCT/CN2025/074454 and an international publication date of August 7, 2025 [1] Group 2 - Huili Pharmaceutical has announced a total of three international patent applications this year, which is a 25% decrease compared to the same period last year [2] - In the 2024 annual report, the company reported a research and development investment of 328 million yuan, reflecting a year-on-year decrease of 3.82% [2]